IndyGeneUS Expands Its Global Advisory Board with Former Department of Veteran Affairs Executive

August 10, 2023 04:30 AM PDT | By EIN Presswire
 IndyGeneUS Expands Its Global Advisory Board with Former Department of Veteran Affairs Executive
Image source: EIN Presswire
WASHINGTON, DC, USA, August 10, 2023/EINPresswire.com/ -- IndyGeneUS strengthens its position as a global leader in digital health transformation by welcoming former Chief Innovation Officer of the Department of Veteran Affairs (VA), Ryan Vega, MD to its global advisory board.

As a former executive to the largest value-based care modeling healthcare system, Dr. Vega was responsible for the significant growth and implementation of enterprise innovation. Dr. Vega brings a deep mix of clinical, technical, and business experience as IndyGeneUS seeks to drive precision health equity throughout the veteran population.

As a service-disabled veteran-owned small business (SDVOSB), Dr. Vega’ advisory support will enable the company to explore various initiatives that affect women and minority veterans throughout the US and globally.

“We are extremely excited to have Dr. Vega as part of our distinguished board," said IndyGeneUS Founder and CEO, Yusuf Henriques. "This is a value-add to IndyGeneUS’ innovative approach to addressing health equity and disparities within clinical trials.”

IndyGeneUS, pronounced indigenous, is a precision health company building the largest blockchain-encrypted repository of diasporic African and indigenous populations clinical and genomic data to democratize precision medicine and expedite the identification of disease drivers, biomarkers, and therapeutic targets for diseases disproportionately impacting underserved and underrepresented populations.

“The work IndyGeneUs is leading holds tremendous promise for where the future of precision medicine can take us - and for an often overlooked population. I am humbled for the opportunity to continue to serve and be a part of the future of global health," says Dr. Ryan Vega.”

To learn more about IndyGeneUS AI and its initiatives - visit IndyGeneUS.ai or for media inquiries contact Angel Livas: [email protected].

Angel Livas
IndyGeneUS AI
+1 202-930-3262
email us here
Visit us on social media:
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Sponsored Articles


Investing Ideas

Previous Next